Comparison of Prohance® With Gadovist®/Gadavist™ in Magnetic Resonance Imaging (MRI) of the Brain
Status:
Completed
Trial end date:
2014-04-01
Target enrollment:
Participant gender:
Summary
This study aims at a direct comparison between ProHance (0.1 mmol/kg) and a validated
comparator Gadovist/Gadavist (0.1 mmol/kg) in a crossover intra-individual design in subjects
with brain tumors to confirm the identical overall technical and diagnostic performance of
the two MR contrast agents.